Get the Stockscreener App
7.48
3.11%
-0.24
After Hours:
7.43
-0.05
-0.67%
Cvrx Inc stock is traded at $7.48, with a volume of 211.01K.
It is down -3.11% in the last 24 hours and down -0.66% over the past month.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
See More
Previous Close:
$7.72
Open:
$7.71
24h Volume:
211.01K
Relative Volume:
0.60
Market Cap:
$196.81M
Revenue:
$56.65M
Net Income/Loss:
$-53.31M
P/E Ratio:
-3.6591
EPS:
-2.0442
Net Cash Flow:
$-40.75M
1W Performance:
-4.47%
1M Performance:
-0.66%
6M Performance:
-22.25%
1Y Performance:
+18.54%
1-Day Range:
$7.26
$7.78
1-Week Range:
$6.645
$8.48
52-Week Range:
$4.2993
$11.30
Cvrx Inc Stock (CVRX) Company Profile
Name
Cvrx Inc
Sector
Industry
Phone
(763) 416-2850
Address
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
7.48 | 203.13M | 56.65M | -53.31M | -40.75M | -2.0442 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-09-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-14-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-10-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-24 | Reiterated | Lake Street | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| May-01-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Lake Street | Buy |
| Jul-18-22 | Initiated | Craig Hallum | Buy |
| Jul-26-21 | Initiated | Canaccord Genuity | Buy |
| Jul-26-21 | Initiated | Piper Sandler | Overweight |
| Jul-26-21 | Initiated | William Blair | Outperform |
View All
Cvrx Inc Stock (CVRX) Latest News
CCORF Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
CVRX Maintained by Canaccord Genuity -- Price Target Steady at $10 - GuruFocus
Lake Street Initiates CVRx Inc(CVRX.US) With Buy Rating, Announces Target Price $14 - 富途牛牛
William Blair reiterates CVRx stock rating on strong Q1 results By Investing.com - Investing.com South Africa
William Blair reiterates CVRx stock rating on strong Q1 results - Investing.com
CVRx Reports 20% Revenue Growth and Improved Medicare Approval Rates in Preliminary Q1 2026 Results - Minichart
CVRx expects robust 20 percent revenue growth in preliminary Q1 results - Traders Union
CVRx Reports Strong Q1 Growth and Trial Progress - TipRanks
CVRx preliminary Q1 revenue rises 20%, gross margin improves - TradingView — Track All Markets
CVRx (NASDAQ: CVRX) posts Q1 growth and advances BENEFIT-HF trial - Stock Titan
CVRx says Medicare approval rates improved as heart device sales rose - Stock Titan
Forecast Cut: Is CVRX a speculative investmentCPI Data & AI Based Buy and Sell Signals - baoquankhu1.vn
Bear Alert: Is CVRx Inc stock overvalued or fairly priced2026 Catalysts & Short-Term High Return Ideas - baoquankhu1.vn
CVRx, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
(CVRX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Pharma News: Will CVRX benefit from government policyDay Trade & Reliable Price Breakout Alerts - baoquankhu1.vn
CVRX Should I Buy - Intellectia AI
Analysis Recap: Can CVRx Inc weather a recession2026 Price Action Summary & Trade Opportunity Analysis - baoquankhu1.vn
CVRX Apr 2026 7.500 call (CVRX260417C00007500) Interactive Stock Chart - Yahoo! Finance Canada
CVRX Apr 2026 10.000 put (CVRX260417P00010000) Interactive Stock Chart - Yahoo! Finance Canada
CVRX Earnings History & Surprises | EPS & Revenue Results | CVRX INC (NASDAQ:CVRX) - ChartMill
CVRx, Inc. (NASDAQ:CVRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Patterns Watch: Is CVRX a speculative investmentPortfolio Profit Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Sectors Review: Is CVRX a strong candidate for buy and holdInsider Buying & Technical Analysis for Trade Confirmation - baoquankhu1.vn
IMA,CVRX Volatility & Greeks - Finviz
How (CVRX) Movements Inform Risk Allocation Models - Stock Traders Daily
CVRx touts Barostim therapy as improving exercise capacity in heart failure beyond GDMT alone - Traders Union
SGP,CVRX Volatility & Greeks - Finviz
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-03-26 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Shareholders to Reach Out | NDAQ:CVRX | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
CVRx, Inc. (NASDAQ:CVRX) Q4 2025 earnings call transcript - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
IMA,CVRX Dividends - Finviz
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Investors to Connect - ACCESS Newswire
CVRx’s BENEFIT-HF Trial: New Heart Failure Study Sets Up a Key Catalyst for Investors - tipranks.com
Bronstein, Gewirtz & Grossman, LLC Encourages CVRx, Inc. (CVRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
CVRx Inc Stock (ISIN: US12674F1003) Gains Momentum on Heart Failure Device Adoption Amid Medtech Sec - AD HOC NEWS
Sentiment Review: Will CVRX benefit from government policy2026 Price Swings & Precise Buy Zone Identification - baoquankhu1.vn
EPS Watch: How is CVRx Inc managing supply chain issuesOptions Play & Daily Stock Momentum Reports - baoquankhu1.vn
Trading Systems Reacting to (CVRX) Volatility - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Stockholders to Connect - ACCESS Newswire
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Continues – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz - The AI Journal
FinancialContentCVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - FinancialContent
CVRx (CVRX) Gets a Buy from Lake Street - The Globe and Mail
Levels Update: Whats the beta of CVRx Inc stock2026 Pullbacks & High Conviction Investment Ideas - baoquankhu1.vn
First Barostim procedure at Ascension Alexian Brothers backed by CVRx - Traders Union
CVRx (CVRX) CMO granted 62K options, 41K RSUs and sells 1.3K shares - Stock Titan
Exit Recap: Will CVRx Inc announce a stock splitMarket Rally & Long-Term Growth Plans - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Cvrx Inc Stock (CVRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cvrx Inc Stock (CVRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hykes Kevin | PRES & CEO |
Mar 02 '26 |
Sale |
7.90 |
7,763 |
61,349 |
284,237 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,284 |
10,146 |
60,551 |
| OASHEIM JARED | CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,744 |
13,781 |
96,703 |
| John Robert Allen | Chief Revenue Officer |
Mar 02 '26 |
Sale |
7.90 |
3,964 |
31,326 |
86,036 |
| Jain Mudit K. | Director |
Feb 20 '26 |
Buy |
6.36 |
46,800 |
297,592 |
980,183 |
| Jain Mudit K. | Director |
Feb 18 '26 |
Buy |
4.64 |
600 |
2,785 |
5,650 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 26 '25 |
Sale |
10.03 |
6,337 |
63,560 |
4,040,861 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 24 '25 |
Sale |
10.06 |
2,200 |
22,132 |
4,047,198 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 21 '25 |
Sale |
10.00 |
500 |
5,000 |
4,049,398 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 12 '25 |
Sale |
10.00 |
1,000 |
10,000 |
4,049,898 |
2.40%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):